TScan Therapeutics (TCRX) Earnings Date & Reports

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TCRX is expected to report earnings to fall 214.73% to -29 cents per share on August 13

TScan Therapeutics TCRX Stock Earnings Reports

Q2'25

Est.

$-0.30

Q1'25

Beat

by $0.54

Q4'24

Missed

by $0.01

Q3'24

Beat

by $0.06

Q2'24

Est.

$-0.28

The last earnings report on May 06 showed earnings per share of 25 cents, beating the estimate of -28 cents. With 244.57K shares outstanding, the current market capitalization sits at 71.87M.

View a ticker or compare two or three

Compare

TCRX